Business
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
Two additional abstracts have been accepted to be presented at upcoming prestigious industry conferences, SIO 2025 and SSO 2025 The accepted abstracts
About this update from Renovorx, Inc.
[{"type":"text","content":"\nTwo additional abstracts have been accepted to be presented at upcoming prestigious industry conferences, SIO 2025 and SSO 2025\n\n\nThe accepted abstracts support RenovoRx’s novel Trans-Arterial Micro-Perfusion (TAMP™) therapy platform via additional human pharmacokinetic (PK) data and pre-clinical data\n\n\n MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--\nRenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced three abstracts were accepted to be presented at several upcoming industry conferences including ASCO Gastrointestinal Cancers Symposium (ASCO GI) 2025, Society of Interventional Oncology (SIO) 2025 and Society of Surgical Oncology (SSO) 2025.\n\n\nThe abstracts support RenovoRx’s novel and patented TAMP therapy platform via additional human PK data and pre-clinical data. TAMP is designed to ensure precise therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy.\n\n\nRenovoRx’s pivotal ongoing Phase III TIGeR-PaC clinical trial is evaluating the Company’s first product candidate, a novel investigational oncology drug-device combination utilizing the Company’s FDA-cleared RenovoCath device via TAMP for the intra-arterial administration of chemotherapy, gemcitabine. RenovoRx currently anticipates completion of both patient enrollment and the second interim analysis for TIGeR-PaC by the end of the first half of 2025.\n\n\nAbstract Details:\n\n\nASCO GI 2025\n\n\n\nTitle: Intra-arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic Sub-study of the TIGeR-PaC Phase 3 Clinical Trial\n\n\n\nAuthors: Paula Novelli MD, Amer Zureikat MD, Michael Pishvaian MD, Kenneth Meredith MD, Hassan Hatoum MD, Emmanuel Zervos MD, Reza Nazemzadeh MD, Sandeep Loria MD, Ramtin Agah MD\n\n\n\nLocation: Moscone West, San Francisco CA\n\n\n\nDate/Time: January 24, 2025 at 11:30 a.m. PT\n\n\n\nSIO 2025\n\n\n\nTitle: Micro-CT imaging following intra-arterial delivery of a radiopaque silicone polymer using a double-balloon occlusion cath...